- Home
- ANVS vs AXDX Comparison
ANVS vs AXDX Comparison
Compare ANVS & AXDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANVS
- AXDX
- Stock Information
- Founded
- ANVS 2008
- AXDX 1982
- Country
- ANVS United States
- AXDX United States
- Employees
- ANVS N/A
- AXDX N/A
- Industry
- ANVS Biotechnology: Pharmaceutical Preparations
- AXDX Biotechnology: Laboratory Analytical Instruments
- Sector
- ANVS Health Care
- AXDX Industrials
- Exchange
- ANVS Nasdaq
- AXDX Nasdaq
- Market Cap
- ANVS 31.2M
- AXDX 27.0M
- IPO Year
- ANVS 2020
- AXDX 1996
- Fundamental
- Price
- ANVS $1.48
- AXDX $0.71
- Analyst Decision
- ANVS Strong Buy
- AXDX Hold
- Analyst Count
- ANVS 5
- AXDX 1
- Target Price
- ANVS $37.00
- AXDX $1.00
- AVG Volume (30 Days)
- ANVS 257.8K
- AXDX 49.1K
- Earning Date
- ANVS 05-12-2025
- AXDX 03-21-2025
- Dividend Yield
- ANVS N/A
- AXDX N/A
- EPS Growth
- ANVS N/A
- AXDX N/A
- EPS
- ANVS N/A
- AXDX N/A
- Revenue
- ANVS N/A
- AXDX $11,698,000.00
- Revenue This Year
- ANVS N/A
- AXDX $7.25
- Revenue Next Year
- ANVS N/A
- AXDX N/A
- P/E Ratio
- ANVS N/A
- AXDX N/A
- Revenue Growth
- ANVS N/A
- AXDX N/A
- 52 Week Low
- ANVS $1.43
- AXDX $0.69
- 52 Week High
- ANVS $20.00
- AXDX $2.09
- Technical
- Relative Strength Index (RSI)
- ANVS 30.83
- AXDX 22.43
- Support Level
- ANVS $1.43
- AXDX $0.69
- Resistance Level
- ANVS $2.07
- AXDX $1.09
- Average True Range (ATR)
- ANVS 0.14
- AXDX 0.11
- MACD
- ANVS 0.04
- AXDX -0.04
- Stochastic Oscillator
- ANVS 7.03
- AXDX 2.93
About ANVS Annovis Bio Inc.
Annovis Bio Inc is a clinical-stage pharmaceutical company focused on developing and commercializing drugs for the treatment of Parkinson's and Alzheimer's diseases and other neurodegenerative diseases. The pipeline products of the company consists of: Buntanetap for chronic neurodegeneration - including AD and PD; ANVS405 for acute neurodegeneration; and ANVS301 for advanced AD.
About AXDX Accelerate Diagnostics Inc.
Accelerate Diagnostics Inc is an in vitro diagnostics company that specializes in rapid diagnostics for infectious pathogens. The firm's core platform, the Accelerate ID/AST System, determines whether live bacterial or fungal cells in a patient sample are susceptible to a particular antibiotic. This test is performed on pathogens that are commonly associated with serious infections and can deliver results more quickly than traditional methods, such as bacterial culturing. The system can analyze a positive blood culture sample in approximately five hours, which is faster than traditional testing techniques. The company earns majority of its revenue from domestic market.